Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent data showing faster heart and blood pressure rates lead some analysts to question the drug maker's strategy for its diabetes drug.
You may also be interested in...
Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
It was all about the pipeline during Eli Lilly’s fourth quarter earnings call, as company execs strove to convince analysts they’ve made progress in efforts to counter revenue losses from big-ticket products about to lose patent protection.
Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
It was all about the pipeline during Eli Lilly’s fourth quarter earnings call, as company execs strove to convince analysts they’ve made progress in efforts to counter revenue losses from big-ticket products about to lose patent protection.
Promising Phase III Data For Roche/Ipsen's Taspoglutide Heats Up GLP-1 Race
Once-weekly human GLP-1 analog taspoglutide shows superior HbA1c reduction to Byetta - and may soon catch Novo's liraglutide.